Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Letsch

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
The Journal of Urology|January 10, 2004
Effective treatment of experimental androgen sensitive and androgen independent intraosseous prostate cancer with targeted cytotoxic somatostatin analogue AN-238Markus Letsch, Andrew V Schally, Karoly Szepeshazi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 14, 2003
Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancersMarkus Letsch, Andrew V Schally, Karoly Szepeshazi, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 23, 2003
Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancersMarkus Letsch, Andrew V Schally, Rebeca Busto, et al.
Urologia Internationalis|February 23, 2010
The worst case: giant exulcerating seminomaMarkus Letsch, Martin Spahn, Matthias Beissert, et al.
The Prostate|July 12, 2002
Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factorArtur Plonowski, Andrew V Schally, Markus Letsch, et al.
International Journal of Cancer|July 9, 2005
Targeted chemotherapy with cytotoxic bombesin analogue AN-215 inhibits growth of experimental human prostate cancersAnton Stangelberger, Andrew V Schally, Markus Letsch, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 16, 2006
Lipopeptide antagonists of growth hormone-releasing hormone with improved antitumor activitiesMarta Zarandi, Jozsef L Varga, Andrew V Schally, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
The Journal of Urology|January 10, 2004
Effective treatment of experimental androgen sensitive and androgen independent intraosseous prostate cancer with targeted cytotoxic somatostatin analogue AN-238Markus Letsch, Andrew V Schally, Karoly Szepeshazi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 14, 2003
Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancersMarkus Letsch, Andrew V Schally, Karoly Szepeshazi, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 23, 2003
Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancersMarkus Letsch, Andrew V Schally, Rebeca Busto, et al.
Urologia Internationalis|February 23, 2010
The worst case: giant exulcerating seminomaMarkus Letsch, Martin Spahn, Matthias Beissert, et al.
The Prostate|July 12, 2002
Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factorArtur Plonowski, Andrew V Schally, Markus Letsch, et al.
International Journal of Cancer|July 9, 2005
Targeted chemotherapy with cytotoxic bombesin analogue AN-215 inhibits growth of experimental human prostate cancersAnton Stangelberger, Andrew V Schally, Markus Letsch, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 16, 2006
Lipopeptide antagonists of growth hormone-releasing hormone with improved antitumor activitiesMarta Zarandi, Jozsef L Varga, Andrew V Schally, et al.
Pageof 1